Morgan Stanley Reiterates Overweight on AlloVir, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has reiterated an Overweight rating on AlloVir (NASDAQ:ALVR) and maintained a $20 price target.
August 07, 2023 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on AlloVir and maintained a $20 price target, indicating a positive outlook for the company.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. An Overweight rating suggests that the analyst believes the stock will outperform its industry in the near term. The maintained price target of $20 indicates that the analyst sees potential for the stock's price to rise to this level.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100